| |
| |
|
| Insider
Information: |
Healy James |
| Relationship: |
Director |
| City: |
Brisbane |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
18 |
|
| Direct
Shares |
4,099,087 |
|
|
Indirect Shares
|
25,091,449 |
|
|
| Direct
Value |
$7,818,018 |
|
|
|
Indirect Value
|
$363,039,295 |
|
|
| Total
Shares |
29,190,536 |
|
|
| Total
Value |
$370,857,313 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
3
|
2
|
|
Stock
price went up :
|
1
|
2
|
| Stock
price went down : |
2
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
2.0
|
| Percentage
Gain/Loss : |
 -34.0%
|
 137.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
InterMune Inc |
ITMN |
Director |
2014-09-29 |
0 |
2005-11-14 |
0 |
Premium* |
|
|
Anthera Pharmaceuticals Inc |
ANTH |
Director |
2012-01-28 |
32,443 |
2011-12-30 |
44,969 |
Premium* |
|
|
Amarin Corp Plc |
AMRN |
Director |
2012-08-31 |
90,000 |
2012-08-31 |
6,321,588 |
Premium* |
|
|
Humanigen Inc |
HGEN |
Director |
2013-02-05 |
0 |
2013-02-05 |
414,394 |
Premium* |
|
|
Ocera Therapeutics Inc |
OCRX |
10% Owner |
2014-03-18 |
9,364 |
2013-07-15 |
0 |
Premium* |
|
|
Hyperion Therapeutics Inc |
HPTX |
Director, 10% Owner |
2015-05-07 |
0 |
2015-05-07 |
0 |
Premium* |
|
|
Coherus Biosciences, Inc. |
CHRS |
Director |
2021-09-29 |
70,086 |
2021-09-29 |
0 |
Premium* |
|
|
Natera, Inc. |
NTRA |
|
2025-04-25 |
46,260 |
2025-04-25 |
1,550,280 |
Premium* |
|
|
PDS Biotechnology Corp |
PDSB |
Director |
2015-10-06 |
0 |
2016-03-11 |
2,852,711 |
Premium* |
|
|
Iterum Therapeutics Plc |
ITRM |
Director, 10% Owner |
2019-05-24 |
6,154 |
2019-05-24 |
1,726,514 |
Premium* |
|
|
Y-Mabs Therapeutics Inc |
YMAB |
|
2025-06-30 |
56,683 |
2025-06-30 |
2,194,278 |
Premium* |
|
|
Karuna Therapeutics, Inc. |
KRTX |
|
2024-03-18 |
0 |
2024-03-18 |
0 |
Premium* |
|
|
Checkmate Pharmaceuticals, Inc. |
CMPI |
10% Owner |
2020-08-11 |
0 |
2020-08-11 |
3,606,707 |
Premium* |
|
|
Bolt Biotherapeutics, Inc. |
BOLT |
Director |
2021-02-09 |
0 |
2021-02-09 |
2,754,437 |
Premium* |
|
|
Jade Biosciences |
JBIO |
10% Owner |
2021-07-02 |
3,758,686 |
2021-07-02 |
0 |
Premium* |
|
|
Cincor Pharma, Inc. |
CINC |
Director, 10% Owner |
2022-08-11 |
29,411 |
2022-08-11 |
6,000 |
Premium* |
|
|
Arrivent Biopharma, Inc. |
AVBP |
Director |
2024-01-30 |
0 |
2024-01-30 |
1,696,752 |
Premium* |
|
|
Rapport Therapeutics, Inc. |
RAPP |
Director |
2024-06-10 |
0 |
2024-07-01 |
1,922,819 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| YMAB |
Y-Mabs Therapeutics Inc |
|
– • – |
2025-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
25,080 |
56,683 |
0 |
- |
|
| NTRA |
Natera, Inc. |
|
– • – |
2025-04-25 |
4 |
A |
$0.00 |
$0 |
D/D |
142 |
46,260 |
0 |
- |
|
| NTRA |
Natera, Inc. |
|
– • – |
2025-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
114 |
46,118 |
0 |
- |
|
| NTRA |
Natera, Inc. |
|
– • – |
2024-10-25 |
4 |
A |
$0.00 |
$0 |
D/D |
153 |
46,004 |
0 |
- |
|
| NTRA |
Natera, Inc. |
|
– • – |
2024-07-26 |
4 |
A |
$0.00 |
$0 |
D/D |
177 |
45,851 |
0 |
- |
|
| RAPP |
Rapport Therapeutics, Inc... |
Director |
– • – |
2024-07-01 |
4 |
B |
$23.08 |
$1,079,575 |
I/I |
44,032 |
40,851 |
2.1 |
% |
|
| NTRA |
Natera, Inc. |
|
– • – |
2024-06-28 |
4 |
A |
$0.00 |
$0 |
D/D |
2,964 |
45,674 |
0 |
- |
|
| YMAB |
Y-Mabs Therapeutics Inc |
Director |
– • – |
2024-06-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,495 |
31,603 |
0 |
- |
|
| RAPP |
Rapport Therapeutics, Inc... |
|
– • – |
2024-06-10 |
4 |
B |
$17.00 |
$9,500,008 |
I/I |
558,824 |
25,455 |
0.01 |
% |
|
| RAPP |
Rapport Therapeutics, Inc... |
|
– • – |
2024-06-10 |
4 |
A |
$0.00 |
$0 |
I/I |
1,392,738 |
1,392,738 |
0 |
- |
|
| NTRA |
Natera, Inc. |
|
– • – |
2024-04-26 |
4 |
A |
$0.00 |
$0 |
D/D |
210 |
42,710 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
|
• • – |
2024-03-18 |
4 |
D |
$330.00 |
$11,051,700 |
D/D |
(33,490) |
0 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
|
• • – |
2024-03-18 |
4 |
D |
$330.00 |
$455,779,170 |
I/I |
(1,381,149) |
0 |
0 |
- |
|
| AVBP |
Arrivent Biopharma, Inc. |
Director |
– • – |
2024-01-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,252,308 |
1,252,308 |
0 |
- |
|
| AVBP |
Arrivent Biopharma, Inc. |
Director |
– • – |
2024-01-30 |
4 |
B |
$18.00 |
$7,999,992 |
I/I |
444,444 |
1,696,752 |
2.1 |
% |
|
| NTRA |
Natera, Inc. |
|
– • – |
2024-01-26 |
4 |
A |
$63.79 |
$16,841 |
D/D |
264 |
42,500 |
0 |
- |
|
| NTRA |
Natera, Inc. |
Director |
– • – |
2023-12-13 |
4 |
S |
$58.75 |
$37,835,000 |
I/I |
(644,000) |
0 |
0 |
% |
|
| NTRA |
Natera, Inc. |
|
– • – |
2023-10-27 |
4 |
A |
$42.60 |
$16,870 |
D/D |
396 |
42,236 |
0 |
- |
|
| NTRA |
Natera, Inc. |
|
– • – |
2023-07-28 |
4 |
A |
$48.48 |
$15,901 |
D/D |
328 |
41,840 |
0 |
- |
|
| NTRA |
Natera, Inc. |
|
– • – |
2023-06-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,750 |
41,512 |
0 |
- |
|
| KRTX |
Karuna Therapeutics, Inc. |
|
– • – |
2023-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
990 |
33,490 |
0 |
- |
|
| YMAB |
Y-Mabs Therapeutics Inc |
Director |
– • – |
2023-06-08 |
4 |
A |
$0.00 |
$0 |
D/D |
2,330 |
28,108 |
0 |
- |
|
| NTRA |
Natera, Inc. |
|
– • – |
2023-05-25 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,534 |
38,762 |
0 |
- |
|
| NTRA |
Natera, Inc. |
|
– • – |
2023-04-14 |
4 |
A |
$54.73 |
$15,598 |
D/D |
285 |
35,228 |
0 |
- |
|
| NTRA |
Natera, Inc. |
|
– • – |
2023-01-13 |
4 |
A |
$40.01 |
$15,604 |
D/D |
390 |
34,943 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
